Overview
 

New grant on sirtuins

Video of Epigenetics Lecture

Surprising Science Video on epigenetics

Phoenix Pharmazie Wissenschaftspreis for Manfred Jung

Renewal for CRC 992 Medical Epigenetics

3rd Freiburg Epigenetic Spring Meeting

Press release on our paper on Spindlin1 inhibitors

Press release on our paper on new sirtuin inhibitors

New COST Action Epigenetic Chemical Biology

New DFG-funded project on HDAC8/10 inhibitors

New project within Research Training Group on cofactors

Eva-Maria Herrlinger wins UniDAZ Science Prize for her Bachelor Thesis

New EU consortium on Epigenetic anti-parasite drugs

DPhG Annual Meeting in Freiburg

SFB 992 Homepage Launched

M. Jung in Science Webinar on Epigenetic Drug Discovery

M. Jung Member of the Editorial Board of the Journal of Biomolecular Screening

M. Jung receives funding in the German Consortium for Translational Cancer Research

M. Jung interviewed on Epigenetics

Author Profile of Manfred Jung in ChemMedChem

New SFB Medical Epigenetics

M. Jung receives funding in KFO 201

M. Jung named as Academic Editor for PLoS ONE

M. Jung appointed as FRIAS fellow

In priority program - SPP 1463

Most accessed article in ChemMedChem 7/2009-6/2010

MedChemWatch: Young Researcher

New COST action "Epigenetics - from bench to bedside"

3sat scobel - Neues über Krebs

FP7 project approved: SEtTReND

Scientific advisor for FP6 project: SMARTER Chromatin

Book: "Epigenetic Targets in Drug Discovery" released

Übersichtsartikel zum Thema Epigenetik

 

 

 

News / Information

   

05/2017 - New grant on sirtuins
The DFG is funding a new collaborative project (together with W. Sippl, Halle) on Isotype selective sirtuin inhibitors.


12/2016 - Video of Epigenetics Lecture
The Freiburg Institute for Advanced Studies (FRIAS) has released the video of an Epigenetics Lecture by A. Ganesan. The lecture was part of the FRIAS Lunch Lecture series "Ignorance - what we don't know".


11/2016 - Surprising Science video on epigenetics
The research portal Surprising Science of the University of Freiburg has released a video on epigenetic research in our group and the CRC 992 Medical Epigenetics.


10/2016 - Phoenix Pharmazie Wissenschaftspreis for Manfred Jung
The Phoenix group has awarded the 2016 Phoenix Pharmazie Wissenschaftspreis to our group in the category Pharmaceutical Chemistry. Basis for the prize is our publication "Selective Sirt2 inhibition by ligand-induced rearrangement of the active site" (Rumpf et al., Nat. Commun. 6 (2015) 6263).
(Pressemitteilung der Uni Freiburg)


5/2016 - Renewal for CRC 992 Medical Epigenetics
The CRC 992 Medical Epigenetics (MEDEP, Speaker: R. Schüle) has been renewed for another four years by the Deutsche Forschungsgemeinschaft (DFG). The Jung group receives funding for a project on methyllysine reader proteins and their inhibitors.


4/2016 - 3rd Freiburg Epigenetics Spring Meeting
The 3rd Freiburg Epigenetics Spring Meeting took place from April 10th to 13th. It was organzied by the FRIAS (Freiburg Institute of Advanced Studies) Project Group "Chemical Epigenetics" (B. Breit, O. Einsle, S. Günther, M. Jung) and the CRC 992 Medical Epigenetics (R. Schüle). A detailed report is available here.


2/2016 - Press release on our paper on Spindlin1 inhibitors (in German)


2015 - Press release on our paper on new sirtuin inhibitors and their structure in complex with Sirt2 (in German)


2014 - New COST Action Epigenetic Chemical Biology
The EU COST program is funding a new initative on Epigenetic Chemical Biology (EPICHEM, Action CM 1406). The key objective of the Action is to establish the first European chemical biology network focused on epigenetics. It will provide common ground for researchers from academia, research institutes, SMEs and multinational organizations. The fruitful interactions between these sectors will lead to the creation of new chemical tools as well as leads for therapeutics and agrochemicals. The Action's further objective is to increase awareness of epigenetics within the European scientific community and it will provide training for ESRs and emphasize inclusiveness by COST priority member countries. M. Jung and C. Gerhäuser (DKFZ) have been appointed as German Management Committee Members. Link to press release


2014 - New DFG-funded project on HDAC8/10 inhibitors
The Deutsche Forschungsgemeinschaft (DFG) is funding a new joint project of the Jung group together with W. Sippl (Halle), I. Oehme and O. Witt (both Heidelberg) on the optimization of inhibitors of the histone deacetylase (HDAC) subtypes 8 and 10. Both HDAC8 and 10 have not received so much attention with regard to drug discovery, but have been identified as potential targets in neuroblastoma. Bioguided optimization of available lead structures should lead to potent and selective inhibitors for probing the biology of these HDACs to further dissect their role as drug targets.


2014 - New project within Research Training Group on cofactors
A new Research training group (Graduiertenkolleg, RTG1976, Speaker A. Bechthold) on "Functional diversity of cofactors in Enzymes" has been funded by the German Science Foundation (DFG). The Jung group will work on the NAD-dependent histone deacetylase smSirt2 from Schistosoma mansoni. For more info see www.cofactor-diversity.uni-freiburg.de.


2014 - Eva-Maria Herrlinger wins UniDAZ Science Prize for her Bachelor Thesis
During this year's Interpharm meeting in Berlin, our student Eva-Maria Herrlinger was awarded the UniDAZ Science Prize for her Bachelor Thesis. Eva studied the structure-activity relationship of novel inhibitors of histone demethylases and deacetylases, which she had synthesized and tested during her Bachelor Thesis project in the Jung group. After obtaining her B. Sc. degree, she has rejoined the group as a student research assistant.


2013 - New EU consortium on Epigenetic anti-parasite drugs
Within the framework of FP-7, the consortium A-PARADDISE (Anti-parasitic drug discovery in epigenetics) will unite 16 groups from five countries to discover new drugs against the major parasites Schistosoma, Plasmodium, Leishmania and Trypanosma using the epigenetic machinery of these pathogens. A-PARADDISE website. German press release.


2013 - DPhG Annual Meeting in Freiburg
The annual meeting of the German Pharmaceutical Society (DPhG) will take place in Freiburg im Breisgau from October 9th through 11th, 2013. The organizing committee is headed by the chairman of the DPhG local group, Manfred Jung.


2013 - SFB 992 Homepage Launched
The official webpage for the recently established Collaborative Research Center 992 Medical Epigenetics (MEDEP) has been launched. You can find further information on the research projects studied as well as the people involved in this consortium on www.sfb992.uni-freiburg.de.


2012 - M. Jung in Science Webinar on Epigenetic Drug Discovery
This webinar presents an introduction into Epigenetics, an overview over different assay formats for screening and case studies.


2012 - M. Jung Member of the Editorial Board of the Journal of Biomolecular Screening
M. Jung is a member of the Editorial Board of the Journal of Biomolecular Screening (JBS). JBS is a leading peer-reviewed journal focusing on drug discovery sciences. It publishes information that enables researchers to evaluate current technologies and incorporate applications to enhance performance and objectives.


2012 - M. Jung receives funding in the German Consortium for Translational Cancer Research
This initiative (Deutsches Konsortium für Translationale Krebsforschung - DKTK) will build up and support translational research units across Germany. Epigenetic drug discovery is one of the research programs within DKTK and the Jung group will be funded from this program.


2012 - M. Jung interviewed on Epigenetics
Manfred Jung was an invited speaker at the COST Conference on Personalized Medicine (Larnaca, Cyprus, 17.-22.06.12) and was interviewed on Epigenetics (see video on YouTube).


2012 - Author Profile of Manfred Jung in ChemMedChem
Featured author in ChemMedChem


2012 - New Collaborative Reserach Centre: SFB 992 Medical Epigenetics (MEDEP)
The German research foundation will fund a new colloborative reserach center for Medical Epigenetics in Freiburg. The project is headed by Roland Schüle and will focus on the analysis of epigenetic regulation from basic understanding to animal models and clinical settings. These findings will be translated into new diagnostic tools and used for the development of new epigenetic inhibitors. M. Jung is a prinicipal investigator in MEDEP and the coordinator of the Integrated Research Training Group. (Press releases University)


2011 - M. Jung receives finding in KFO 201
Funding for the clinical research unit »Polycystic Kidney Disease - from Model Organisms to Novel Therapies« (KFO 201) has been extended by the Deutsche Forschungsgemeinschaft for three more years. M. Jung has joined now this group as a principal investigator in a joint project (Regulation of ciliogenesis and ciliary disassembly by nephrocystins) with Prof. G. Walz (Nephrology, University Freiburg Medical Centre) to search for new potential drugs for the treatment of polycystic kidney disease.


2011 - M. Jung named as Academic Editor for PLoS One
Manfred Jung served (2011-2014) as an Academic Editor for PLoS ONE. PLoS ONE is a peer-reviewed open-access journal that features reports of original research from disciplines in science and medicine.


2011 - "Structure based epigenetic drug discovery" elected as FRIAS interdisciplinary research group.
The application of Professors O. Einsle (Organic Chemistry and Biochemistry), Prof. Jung and Prof. Sippl (Medicinal Chemistry, University of Halle) on structure based epigenetic drug discovery has been elected by the FRIAS (Freiburg Institute for Advanced Studies) as an Interdisciplinary research group for 2011/12.
Projekt/Project; Fellows


2010 - Prof. Jung receives funding in priority program "Epigenetic regulation of normal hematopoiesis and its dysregulation in myeloid neoplasia" (SPP 1463)
(SPP 1463 Homepage, DFG entry)


2010 - Most accessed article in ChemMedChem 7/2009-6/2010 - Most cited in 2009/2010
Strategies towards inhibitors of histone methyltransferases and demethylases. A. Spannhoff, A.-T. Hauser, R. Heinke, W. Sippl, M. Jung; ChemMedChem. 4 (2009) 1568-1582. This review deals with the involvement of histone methyltransferases and demethylases in human disease and presents an overview over the available inhibitors.


2010 - MedChemWatch: Young Researcher
Presentation of our research profile


2010 - New COST action "Epigenetics - from bench to bedside"
The objective of this Action is to unite synthetic chemists and chemical biologists working in epigenetics, and attract new researchers to the area. The Action will create a pan-European framework for networking and research collaborations in epigenetics. It will feature a unique crossdisciplinary approach that brings together chemists, biologists, pharmacologists and clinicians. This will enable a focus on both innovative and translational science that targets grand challenges within this area. The Action will feature participation from academia, multinational pharmaceutical companies and small to medium enterprises.


2010 - 3sat: scobel - Neues über Krebs
Mit Manfred Jung, Otmar Wiestler (Vorsitzender des Stiftungsvorstandes des Deutschen Krebsforschungszentrums) und Susanne Vössing (Sterneköchin und Expertin für angepasste Ernährung für Patienten in onkologischer Behandlung)


2009 - FP7 project approved: SEtTReND
SEtTReND is a collaborative EU-project (FP7-HEALTH-2009-single-stage) that will deal with identification of epigenetic drug targets in the pathogen Schistosoma mansoni and the discovery of small molecule inhibitors of these enzymes that may serve as new future antiparasital drugs.


2009 - Scientific advisor for FP6 project: SMARTER Chromatin
M. Jung has been appointed as scientific advisor to the EU FP6 program "SMARTER Chromatin". The SMARTER Network consists of four research groups with high expertise in chromatin research and Chroma Therapeutics, a company focused on the generation of cancer and inflammation treatments. The SMARTER project aims at the development and improvement of compounds targeting epigenetic regulators.


2009 - Book: "Epigenetic Targets in Drug Discovery" released
This reference edited by W. Sippl and M. Jung covers everything a drug researcher needs to know about targeting epigenetic mechanisms of disease. The book is divided into sections on methodology (such as molecular modelling, chromatin immunoprecipitation - ChIP or screening assays) and chapters on epigenetic enzymes as drug targets and available inhibitors.


Übersichtsartikel zum Thema Epigenetik
In diesem Artikel wird eine allgemeine Einführung in das Thema Epigenetik und die auf diesem Gebiet bereits zugelassenen Arzneistoffe gegeben. Die Literaturliste zu diesem Artikel finden Sie hier.

   
   
   
   
 

 

 

 
     
© 2007-2017 by ijou.de/sign Impressum